hydroxynefazodone

an active metabolite of the antidepressant nefazodone; structure given in first source

Also Known As:

3H-1,2,4-Triazol-3-one, 2-(3-(4-(4-chlorophenyl)-1-piperazinyl)propyl)-2,4-dihydro-5-(1-hydroxyethyl)-4-(2-phenoxyethyl)-

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

1.	Liver Cirrhosis (Hepatic Cirrhosis) 10/01/1995 - "Subjects with liver cirrhosis had about a two-fold greater systemic exposure to nefazodone and hydroxynefazodone compared with normal subjects after a single dose of nefazodone, the difference decreasing to approximately 25% at steady state. " 01/01/1995 - "The single-dose pharmacokinetics of nefazodone (NEF) and its metabolites hydroxynefazodone (HO-NEF) and m-chlorophenylpiperazine (mCPP) were examined in 12 healthy younger subjects < or = 55 years of age (YNG), 12 elderly subjects > or = 65 years of age (ELD), 12 patients with biopsy proven hepatic cirrhosis (HEP) and 12 patients with moderate renal impairment (REN), ClCR 20-60 ml.min-1. "
2.	Fibrosis (Cirrhosis) 10/01/1995 - "To compare the single- and multiple-dose pharmacokinetics of nefazodone and its three pharmacologically active metabolites, hydroxynefazodone, m-chlorophenylpiperazine, and triazoledione, in patients with biopsy-proven cirrhosis and age-, sex-, and weight-matched healthy volunteers. "